Position on Key Issues
In our focus to help patients with serious diseases, we have developed clear positions on important policies and topics related to healthcare, regulatory, intellectual property and pricing. Learn more about our positions below.
ESG Governance and Operating Model (PDF)
Sound Environmental, Social and Governance (ESG) management practices and oversight are considered to be a strategic component of businesses that are successful over the long term, helping enhance shareholder value as well as delivering benefits to all of our stakeholders. Read more about our ESG governance and operating model.
Access to Medicines in the Developing World
Bioethics Policy Statement (PDF)
Biosimilars
Clinical Trial Communication Commitment
Counterfeit Drugs
Early Patient Access to Investigational Medicines
Generics
Interactions with Health Care Providers - Sunshine Act (US)
Pricing
How We Price Our Medicines
PhRMA's Code on Interactions with Health Care Professionals
PhRMA's Guiding Principles on Direct-to-Consumer Advertisements
Policy and Advocacy Engagement and Political Contributions
Sustaining Our Intellectual Property
U.S. Health Care Reform
Support for European Patient Organizations
As part of our mission to discover, develop and deliver innovative medicines that help patients prevail over serious diseases, Bristol Myers Squibb and the Bristol Myers Squibb Foundation support patient organizations across Europe through partnerships, grants and charitable contributions.